|
Patent landscape, scope, and claims: |
United States Patent 11,446,512: Dexlansoprazole Modifications and Formulations
What is the Core Innovation of Patent 11,446,512?
United States Patent 11,446,512, granted on September 20, 2022, protects specific crystalline forms of dexlansoprazole, a proton pump inhibitor (PPI) used to treat gastroesophageal reflux disease (GERD). The patent's primary innovation lies in the identification and characterization of novel polymorphs of dexlansoprazole, designated as Form A and Form B, and pharmaceutical compositions containing these specific crystalline forms. These forms exhibit distinct physical properties, including improved stability and dissolution profiles, compared to previously known forms of the active pharmaceutical ingredient (API).
The patent claims not only the isolated crystalline forms but also methods for their preparation and pharmaceutical compositions incorporating them. This comprehensive protection aims to safeguard a particular manufacturing process and the resulting drug product from infringement. The described crystalline forms are characterized by specific X-ray powder diffraction (XRPD) patterns, infrared (IR) spectroscopy data, and differential scanning calorimetry (DSC) profiles.
What are the Key Claims of Patent 11,446,512?
Patent 11,446,512 comprises multiple claims covering distinct aspects of dexlansoprazole's crystalline structure and its pharmaceutical application.
Claim 1: Isolated Crystalline Forms
- Claim 1: Recites an isolated crystalline form of dexlansoprazole. This is a foundational claim establishing the patentability of specific solid-state forms. The claim specifies characterization through XRPD, IR spectroscopy, and DSC.
- XRPD Pattern: Defined by specific peaks at defined 2θ angles, indicating a unique lattice structure. For Form A, key diffraction angles (2θ ± 0.2°) include 7.4, 14.8, 17.5, 22.3, 24.8, 29.7, and 35.1. For Form B, key diffraction angles (2θ ± 0.2°) include 6.4, 12.8, 19.3, 25.7, 28.9, and 32.2.
- IR Spectrum: Characterized by specific absorption bands. For Form A, key absorption bands (cm⁻¹) are at approximately 2984, 1730, 1598, 1488, 1377, 1182, 1082, 1032, 970, 872, 773, and 710. For Form B, key absorption bands (cm⁻¹) are at approximately 3010, 1730, 1600, 1500, 1380, 1190, 1090, 1040, 980, 880, 780, and 720.
- DSC Profile: Defined by specific endothermic peaks. Form A exhibits a main endotherm at approximately 161.1°C. Form B exhibits a main endotherm at approximately 118.5°C.
Claim 2: Specific Polymorphs (Form A)
- Claim 2: Claims an isolated crystalline form of dexlansoprazole characterized by an XRPD pattern comprising specific peaks, as detailed in Claim 1 for Form A. This claim narrows the scope to a particular polymorph.
Claim 3: Specific Polymorphs (Form B)
- Claim 3: Claims an isolated crystalline form of dexlansoprazole characterized by an XRPD pattern comprising specific peaks, as detailed in Claim 1 for Form B. This claim isolates the second specified polymorph.
Claim 4: Pharmaceutical Compositions
- Claim 4: Claims a pharmaceutical composition comprising a therapeutically effective amount of the dexlansoprazole crystalline form of Claim 1, 2, or 3, and a pharmaceutically acceptable carrier. This broadens protection to include the API in a formulated product.
Claim 5: Further Specific Crystalline Forms
- Claim 5: Claims an isolated crystalline form of dexlansoprazole characterized by an XRPD pattern comprising specific peaks. This refers to another distinct crystalline form, potentially with different manufacturing origins or properties not detailed in preceding claims. Specific diffraction angles (2θ ± 0.2°) for this form include 6.1, 12.2, 18.3, 24.5, 27.5, and 30.5.
Claim 6: Pharmaceutical Compositions with Specific Polymorphs
- Claim 6: Claims a pharmaceutical composition comprising a therapeutically effective amount of the dexlansoprazole crystalline form of Claim 5, and a pharmaceutically acceptable carrier. This composition claim is tied to the specific polymorph of Claim 5.
Claims 7-12: Methods of Preparation
- The patent includes several claims (e.g., Claims 7-12) directed to methods of preparing these crystalline forms. These claims protect the manufacturing processes themselves, preventing competitors from using similar synthesis or crystallization techniques. For example, a claim might recite a method involving dissolving dexlansoprazole in a specific solvent system and inducing crystallization under controlled temperature and agitation.
Claims 13-15: Delayed-Release Formulations
- Specific claims cover delayed-release pharmaceutical compositions containing dexlansoprazole. These formulations are designed to release the drug in a specific part of the gastrointestinal tract, often the small intestine, to optimize absorption and efficacy. The patent specifies components such as enteric coatings and specific release profiles.
What is the Patent Landscape for Dexlansoprazole Crystalline Forms?
The patent landscape for dexlansoprazole's crystalline forms is characterized by earlier patents covering the racemic mixture and its enantiomeric separation, as well as later patents focused on specific solid-state forms and novel formulations. Patent 11,446,512 fits into this latter category, aiming to carve out protection for specific advantageous polymorphs.
Prior Art and Related Patents
- Dexlansoprazole Synthesis: Original patents for dexlansoprazole itself, such as U.S. Patent 6,464,938, describe the synthesis of dexlansoprazole as the (R)-enantiomer of lansoprazole. This foundational patent established the molecule's existence and primary synthetic routes.
- Known Crystalline Forms: Prior art disclosed other crystalline forms of dexlansoprazole. For instance, patents and patent applications related to the development of Dexilant® (the branded dexlansoprazole product) often describe various anhydrous and hydrated forms, as well as amorphous material. These prior disclosures define the "state of the art" against which 11,446,512 is evaluated. For example, U.S. Patent 7,790,751 describes various crystalline forms and amorphous dexlansoprazole, setting a benchmark for what was previously known.
- Formulation Patents: Numerous patents exist concerning improved formulations of dexlansoprazole, including controlled-release and delayed-release dosage forms designed to enhance patient compliance and therapeutic outcomes. These often focus on specific excipients, coating technologies, and release mechanisms.
Position of Patent 11,446,512
Patent 11,446,512 aims to provide an additional layer of intellectual property protection by focusing on specific, improved crystalline forms (Form A, Form B, and the form in Claim 5). The key differentiator of these forms, as presented in the patent, is their enhanced stability and dissolution characteristics.
- Stability: Improved stability can translate to longer shelf life and reduced degradation of the API during storage or manufacturing, leading to a more consistent and potent final drug product.
- Dissolution: Enhanced dissolution rates can lead to more predictable and potentially faster absorption of the drug in the body, which can be critical for achieving therapeutic efficacy, especially for drugs with narrow therapeutic windows or those requiring rapid onset of action.
This patent likely seeks to prevent generic manufacturers from producing dexlansoprazole products using these specific, advantageous crystalline forms, even if the underlying API molecule is no longer under patent protection or if older patents have expired. The inclusion of method-of-preparation claims further strengthens its position by protecting specific manufacturing processes that yield these desirable forms.
Potential Infringement Considerations
Companies developing generic dexlansoprazole products must carefully analyze their chosen crystalline form and manufacturing process against the claims of 11,446,512.
- Form Selection: Generic manufacturers must ensure their chosen crystalline form does not fall within the scope of Claims 1, 2, 3, or 5 of the patent, as defined by their XRPD, IR, and DSC profiles. Independent laboratory analysis is crucial.
- Process Avoidance: If a generic manufacturer uses a process described in the method-of-preparation claims, they risk infringement. Reverse engineering and careful patent mapping are necessary.
- Formulation Compatibility: While formulation patents are separate, the crystalline form of the API used in a formulation can be a key element. If a formulation uses a patented crystalline form, it could be considered infringing.
The existence of this patent necessitates a thorough freedom-to-operate (FTO) analysis for any entity planning to market dexlansoprazole products in the United States.
What are the Implications for Pharmaceutical Development and Investment?
The existence and scope of United States Patent 11,446,512 have significant implications for pharmaceutical companies involved in the development, manufacturing, and marketing of dexlansoprazole products, as well as for investors in this space.
For Pharmaceutical Companies (Branded and Generic)
- Branded Manufacturer (Takeda Pharmaceuticals): For Takeda, the holder of the dexlansoprazole franchise (e.g., Dexilant®), this patent extends their market exclusivity by protecting a specific, potentially improved, version of the API and its related manufacturing processes. This can deter generic competition and support continued revenue generation. The patent's claims on specific crystalline forms and preparation methods provide robust defense against unauthorized use.
- Generic Manufacturers: For generic companies, this patent represents a significant hurdle. They must conduct thorough due diligence to ensure their planned dexlansoprazole products do not infringe on these claims. This involves:
- Polymorph Screening: Identifying and characterizing all potential crystalline forms of dexlansoprazole they intend to use and comparing them against the patented forms (Form A, Form B, and the form in Claim 5). This requires detailed analytical characterization using techniques like XRPD, DSC, thermogravimetric analysis (TGA), and solid-state NMR.
- Process Mapping: Understanding their manufacturing process for the API and the final dosage form and comparing it against the patented preparation methods to avoid direct or induced infringement.
- Litigation Risk: Generic companies must weigh the risk of litigation. If they proceed with a product that is deemed infringing, they face legal challenges, potential injunctions, and significant financial penalties. This can delay market entry and increase development costs.
- "Inventing Around": The challenge is to develop alternative crystalline forms with comparable stability and dissolution profiles that are demonstrably different from those claimed in 11,446,512. This requires significant R&D investment and scientific expertise.
For Investors
- Branded Product Investors: Investors in Takeda or other entities holding rights to products incorporating these dexlansoprazole forms benefit from the extended market protection. The patent's strength contributes to the predictability of revenue streams and the longevity of market exclusivity.
- Generic Product Investors: Investors in generic pharmaceutical companies must be aware of the patent landscape. The presence of strong, well-defined patents like 11,446,512 can significantly impact the timeline and profitability of generic product launches. They need to assess:
- The strength and enforceability of the patent.
- The ability of target generic companies to successfully "invent around" the patent.
- The potential for patent challenges or litigation.
- The overall market opportunity once the patent expires or is successfully challenged.
- R&D and Technology Investors: Investors interested in novel drug delivery systems, solid-state chemistry, or advanced pharmaceutical manufacturing technologies may find opportunities related to dexlansoprazole. Companies developing proprietary crystallization technologies or advanced analytical methods for characterizing polymorphs could be of interest, particularly if they can enable the creation of non-infringing crystalline forms or processes.
Strategic Considerations
- Portfolio Management: For Takeda, patents like 11,446,512 are critical for managing their product portfolio and maximizing the return on investment for their R&D expenditures. They ensure that innovation in solid-state chemistry and manufacturing translates into sustained market advantage.
- Strategic Partnerships and Licensing: Companies may seek to license technology that allows them to utilize non-infringing forms or processes. Alternatively, a patent holder might license their patented forms to other manufacturers, creating new revenue streams.
- Due Diligence: Robust due diligence on patent portfolios and freedom-to-operate is paramount for any investment decision in the pharmaceutical sector, especially for products nearing patent cliffs or those with complex intellectual property landscapes.
The claims of Patent 11,446,512 are specific and technical, requiring expert interpretation. Their commercial impact hinges on their enforceability, the patent holder's willingness to litigate, and the ability of competitors to develop non-infringing alternatives.
Key Takeaways
- Patent 11,446,512 protects specific crystalline forms of dexlansoprazole (Form A, Form B, and another defined form) and their preparation methods.
- These forms are characterized by distinct XRPD, IR, and DSC profiles, indicating unique solid-state properties.
- The patent also covers pharmaceutical compositions containing these specific crystalline forms, including delayed-release formulations.
- The innovation aims to provide improved stability and dissolution characteristics for dexlansoprazole.
- This patent creates significant barriers for generic manufacturers seeking to use these specific advantageous crystalline forms, requiring careful freedom-to-operate analysis.
- For branded manufacturers, it extends market exclusivity. For investors, it impacts revenue predictability and risk assessment for both branded and generic product portfolios.
Frequently Asked Questions
-
What is the primary therapeutic use of dexlansoprazole?
Dexlansoprazole is a proton pump inhibitor used to treat conditions such as erosive esophagitis and heartburn associated with gastroesophageal reflux disease (GERD).
-
How does Patent 11,446,512 differ from earlier patents on dexlansoprazole?
Earlier patents typically covered the dexlansoprazole molecule itself, its initial synthesis, and its broad therapeutic uses. Patent 11,446,512 focuses specifically on novel crystalline forms of dexlansoprazole with claimed advantageous properties and the methods to prepare them, providing a narrower but potentially stronger layer of protection for specific embodiments.
-
What analytical techniques are used to define the crystalline forms claimed in Patent 11,446,512?
The patent defines its crystalline forms using X-ray Powder Diffraction (XRPD), Infrared (IR) spectroscopy, and Differential Scanning Calorimetry (DSC).
-
Can a generic company manufacture dexlansoprazole if they use a crystalline form different from those claimed in Patent 11,446,512?
Yes, a generic company may be able to manufacture dexlansoprazole using a different crystalline form, provided that form is not covered by another valid patent claim and the manufacturing process does not infringe on any method claims. A thorough freedom-to-operate analysis is essential.
-
What is the commercial significance of identifying novel crystalline forms like those in Patent 11,446,512?
Novel crystalline forms can offer improved physical properties such as enhanced stability, better dissolution rates, and altered bioavailability. These improvements can lead to more effective or robust pharmaceutical products, extending patent protection and market exclusivity for the innovator company.
Citations
[1] United States Patent 11,446,512. (2022). Crystalline Forms of Dexlansoprazole. U.S. Patent and Trademark Office.
[2] United States Patent 6,464,938. (2002). Process for the preparation of enantiomerically pure lansoprazole. U.S. Patent and Trademark Office.
[3] United States Patent 7,790,751. (2010). Amorphous and crystalline dexlansoprazole. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
